Drug Repositioning¶
Develop a new therapeutic indication for an existing or previously investigated drug by reusing applicable knowledge while generating the indication-specific evidence still required.
Core Idea¶
Drug repositioning is the investigation and development of an existing or previously investigated drug for a therapeutic indication different from the one that motivated its original development or established use. The starting asset may be approved, shelved, discontinued, generic, or clinically investigated. Repositioning reuses whatever is genuinely transferable—chemistry, manufacturing, pharmacokinetics, toxicology, human exposure, or delivery experience—while generating the evidence needed for the new disease, population, dose, route, formulation, combination, and claim.
Candidates can arise serendipitously from clinical observation or systematically from target/pathway knowledge, phenotypic screening, omics signatures, genetics, adverse-event signals, electronic health records, molecular docking, network models, or cross-disease mechanisms.
Scope of Application¶
Repositioning is used across common, rare, neglected, infectious, oncologic, neurologic, and psychiatric diseases. It is especially attractive where mechanistic overlap exists, human exposure data are available, development resources are constrained, or a shelved compound has a usable safety margin. Sildenafil, thalidomide, and several oncology and rare-disease uses illustrate different routes from observation to new indication.
The strategy can shorten or de-risk parts of development, but savings are conditional. A new route, higher exposure, chronic use, pediatric population, pregnancy context, combination, or formulation may reopen substantial nonclinical and Phase I obligations. Generic availability can also weaken the incentive to fund expensive trials.
Clarity¶
“Existing” must be defined. Some programs restrict the term to approved drugs; others include discontinued or clinical-stage assets. The draft should state asset status and whether “repurposing” and “repositioning” are treated as synonyms.
Reused evidence is not a blanket exemption. Transfer depends on active ingredient, impurities, formulation, route, exposure, population, duration, and endpoint. Regulatory reliance routes such as the U.S.
Manages Complexity¶
Prior knowledge narrows the search and can bypass some early uncertainties. Drug–target–disease networks organize heterogeneous evidence; target product profiles turn a promising observation into explicit requirements; staged validation retires mechanism, exposure, efficacy, safety, and feasibility risks in sequence.
Repositioning also inherits complex history. Published data can be incomplete, shelved-compound records inaccessible, negative results unpublished, and old formulations unavailable.
Abstract Reasoning¶
- Define the new clinical need and target product profile. 2. Establish the asset’s identity, ownership, status, manufacturing route, and prior evidence. 3. Generate a drug–disease hypothesis through mechanistic or phenotype-linked evidence. 4. Triangulate the signal across independent data types and rule out artifacts. 5. Confirm target engagement or phenotypic activity at clinically achievable exposure. 6. Audit transferable versus nontransferable CMC, PK, toxicology, and trial evidence.
Knowledge Transfer¶
The transferable pattern is to reuse a partially validated asset in a new problem context while explicitly auditing which guarantees survive the transfer. Platform reuse, technology transfer, and case-based design share that logic.
The proposed immediate parent is Translational Research: repositioning is a specialized route for moving biological and clinical evidence into an evaluated therapy.
Relationships to Other Abstractions¶
Current abstraction Drug Repositioning Domain-specific
Parents (1) — more general patterns this builds on
-
Drug Repositioning is a kind of Translational Research Domain-specific
Translational Research is the proposed immediate parent.
Hierarchy paths (2) — routes to 2 parentless roots
- Drug Repositioning → Translational Research → Translation and Conceptual Bridging → Representation → Abstraction
- Drug Repositioning → Translational Research → Translation and Conceptual Bridging → Transformation → Function (Mapping)
Neighborhood in Abstraction Space¶
Drug Repositioning sits in a sparse region of the domain-specific corpus (95th percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.
Family — Unclustered & Miscellaneous (1565 abstractions)
Nearest neighbors
- Adverse Event Prediction — 0.82
- Continuous Individualized Risk Index — 0.79
- Translational Research — 0.76
- Elimination Diet — 0.76
- Allelic Heterogeneity — 0.75
Computed from structural-signature embeddings · 2026-09-08